India's Richest People 2026 edition · 1 director · Source: Hurun India
- #272 Naresh Trehan ₹13,800 Cr
GHL Pharma & Diagnostic Private Limited
GHL Pharma & Diagnostic Private Limited - healthcare in Delhi, India. FY 2026 financials & compliance.
Active Private Limited Company healthcare
Revenue · FY 2025
₹106.96 Cr
▲ 392% YoY
Net loss · FY 2025
₹13.35 Cr
Net margin -12.5%
EBITDA · FY 2025
-₹7.48 Cr
EBITDA margin -7%
Authorised capital
₹15 Cr
Registered with MCA
Paid-up capital
₹10.01 Cr
Issued & subscribed
Company age
4 yrs
Est. 2022
Employees · EPFO
170
Provident fund records
Directors on board
3
As per MCA filings
About GHL Pharma & Diagnostic Private Limited
Data last updated:
GHL Pharma & Diagnostic Private Limited is a private limited company based in Delhi, India, a subsidiary of Global Health Limited. It operates in the diagnostic centers and pathology labs segment of the healthcare sector. It was incorporated on 29 June 2022.
Its director Naresh Trehan is #272 among India's richest people (2026).
The company is registered with the Registrar of Companies (ROC), Delhi, under CIN U85110DL2022PTC400942. Its GSTIN is 07AAJCG8809P1ZT (Delhi). The company holds 13 GST registrations, all of them active.
The company has an authorised share capital of ₹15 Cr and a paid-up capital of ₹10.01 Cr. It was formerly known as Global Health Pharmaceutical Private Limited. It is led by directors including Yogesh Kumar Gupta and Naresh Trehan.
Its last annual general meeting (AGM) was held on 18 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at E – 18 Defence Colony, Delhi, India – 110024.
As per the financials filed for FY 2025, the company reported a revenue of ₹106.96 Cr, reflecting significant growth compared to the previous year. For the same year it recorded a net loss of ₹13.35 Cr (net margin -12.5%) and EBITDA of -₹7.48 Cr (EBITDA margin -7%).
The company has about 170 employees on its provident fund (EPFO) records.
Company details
CIN U85110DL2022PTC400942
Registration Number 400942
Incorporation Date 29 June 2022
ROC Delhi
Listing Status Unlisted
Company Status Active
Date of Last AGM 18 September 2025
Date of Balance Sheet 31 March 2025
Parent Company Global Health Limited
Recognitions & Rankings of GHL Pharma & Diagnostic
Contact details
GHL Pharma & Diagnostic Private Limited's registered office is in Delhi, Delhi. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Registered AddressE – 18 Defence Colony, Delhi, India – 110024
- IndustryHealthcare, Diagnostic Centers & Pathology Labs
To see the full contact details of GHL Pharma & Diagnostic Private Limited, buy the company report.
Comprehensive company report
GHL Pharma & Diagnostic Private Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Business activity
The main business activity of GHL Pharma & Diagnostic is hospital and medical care. In detail, this covers other hospital and medical care activities.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| Q | Hospital and Medical Care | Q6 | Other Hospital and Medical Care Activities |
To see the full business activity and turnover split of GHL Pharma & Diagnostic Private Limited, buy the company report.
Financials of GHL Pharma & Diagnostic Private Limited
FY 2025 filings availableGHL Pharma & Diagnostic Private Limited reported revenue of ₹106.96 Cr (up 392% YoY) for FY 2025.
Revenue · FY 2025
₹106.96 Cr ▲ 392%
Net loss · FY 2025
₹13.35 Cr margin -12.5%
EBITDA · FY 2025
-₹7.48 Cr margin -7%
Compounded Annual Growth Rate (CAGR)
Revenue CAGR growth
1 year
▲ 392%
EBITDA CAGR growth
1 year
▲ 28%
Revenue rose 392% in the latest year. EBITDA rose 28% in the latest year. All are worked out from the filed statements.
Financial Statement Summary
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|
| Profit and Loss Statement | |||
| Revenue from Operations | |||
| Other Income | |||
| Total Revenue | |||
| Cost of Materials Consumed | |||
| Employee Benefit Expense | |||
| Finance Costs | |||
| Depreciation and Amortisation | |||
| Other Expenses | |||
| Total Expenses | |||
| EBITDA | -₹7.48 Cr | ||
| Profit Before Tax | |||
| Tax Expense | |||
| Net Profit (PAT) | -₹13.35 Cr | ||
| Balance Sheet | |||
| Share Capital | |||
| Reserves and Surplus | |||
| Net Worth (Total Equity) | |||
| Long-term Borrowings | |||
| Short-term Borrowings | |||
| Trade Payables | |||
| Total Liabilities | |||
| Fixed Assets | |||
| Investments | |||
| Inventories | |||
| Trade Receivables | |||
| Cash and Bank Balance | |||
| Total Assets | |||
Financial Ratios
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 |
|---|---|---|---|
| Profitability | |||
| EBITDA Margin | -7% | ||
| Net Profit Margin | -12.5% | ||
| Return on Equity (ROE) | |||
| Return on Capital Employed (ROCE) | |||
| Return on Assets (ROA) | |||
| Liquidity and Debt | |||
| Current Ratio | |||
| Quick Ratio | |||
| Debt-to-Equity Ratio | |||
| Interest Coverage Ratio | |||
| Efficiency and Growth | |||
| Asset Turnover | |||
| Receivable Days | |||
| Payable Days | |||
| Inventory Days | |||
| Revenue Growth | |||
| Net Profit Growth | |||
To see the full financial statements and ratios of GHL Pharma & Diagnostic Private Limited, buy the company report.
Board of directors of GHL Pharma & Diagnostic Private Limited
GHL Pharma & Diagnostic has 3 current directors and 5 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Yogesh Kumar Gupta | Director | 20 Mar 2024 | 2 Years 7 Months | Current |
| Naresh Trehan | Director | 29 Jun 2022 | 4 Years 4 Months | Current |
| Pankaj Prakash Sahni Also directs: Global Health Limited, Global Health Institute of Medical Sciences Foundation, Global Health Patliputra Private Limited and 1 more | Director | 29 Jun 2022 | 4 Years 4 Months | Current |
Auditor
GHL Pharma & Diagnostic Private Limited is audited by Walker Chandiok & Co LLP for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| Walker Chandiok & Co LLP | FY 2023 | 001076N/N500013 |
Shareholding
The shareholding of GHL Pharma & Diagnostic Private Limited is on record for FY 2023, split between promoters, domestic institutions, foreign institutions, public shareholders and others.
| Shareholder category | FY 2023 |
|---|---|
| Promoters | |
| Domestic institutional investors (DII) | |
| Foreign institutional investors (FII) | |
| Public | |
| Others |
To see the full shareholding pattern of GHL Pharma & Diagnostic Private Limited, buy the company report.
Legal cases
No court or tribunal cases involving GHL Pharma & Diagnostic Private Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
GHL Pharma & Diagnostic Private Limited has 5 MSME Form 1 returns on record for the period ending Mar 2024, listing 449 overdue payments to 48 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 48)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Rallith Medisystems Private Limited | |||
| Sawaliya Distributors LLP. | |||
| Recombigen Laboratories Private Limited | |||
| Bestime Trading Company Private Limited | |||
| Embee Healthcare Private Limited |
To see the full MSME payment records of GHL Pharma & Diagnostic Private Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Employees & EPFO
GHL Pharma & Diagnostic Private Limited has a workforce of 170 employees on its EPFO records as of Apr 06, 2024, across 1 active EPFO establishment.
Employee count
170
Active EPFO establishments
1
Employee growth
95.4%
GST
GHL Pharma & Diagnostic has 13 GST registrations: 13 active. The first 4 active GSTINs are listed below.
Total GSTINs
13
Active
13
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 07AAJCG8809P1ZT | Delhi | Active | 14 Jul 2022 |
| 07AAJCG8809P2ZS | Delhi | Active | 26 Jan 2023 |
| 06AAJCG8809P1ZV | Haryana | Active | 26 Nov 2022 |
| 23AAJCG8809P1ZZ | Madhya Pradesh | Active | 02 Jan 2023 |
To see the full GST registrations and return filing status of GHL Pharma & Diagnostic Private Limited, buy the company report.
Recent activity
GHL Pharma & Diagnostic Private Limited has 8 board changes on record since 2022: 4 appointments and 4 cessations. The latest: Yogesh Kumar Gupta ceased to be Additional Director on 16 Sep 2024.
AGM
Ghl Pharma & Diagnostic Private Limited last Annual general meeting of members was held on 18 Sep 2025 as per latest MCA records.
Filing
Ghl Pharma & Diagnostic Private Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Delhi.
Ceased
Yogesh Kumar Gupta ceased to be Additional Director.
Appointed
Yogesh Kumar Gupta was appointed as Director.
Ceased
Sanjeev Kumar ceased to be Director.
Ceased
Rajdeep Panwar ceased to be Additional Director.
Ceased
Umesh Kumar Mantri ceased to be CFO.
Appointed
Rajdeep Panwar was appointed as Manager.
Appointed
Naresh Trehan was appointed as Director.
Appointed
Pankaj Prakash Sahni was appointed as Director.
Incorporation
29 Jun 2022
Ghl Pharma & Diagnostic Private Limited was registered on 29 Jun 2022 with Roc Delhi & aged 4 years 4 months as per MCA records.
Frequently asked questions
GHL Pharma & Diagnostic is an active private limited company based in Delhi, India. The company works in diagnostic centers and pathology labs, within the healthcare industry. It was incorporated on 29 June 2022 (4+ years old) and is registered under CIN U85110DL2022PTC400942.
GHL Pharma & Diagnostic has 3 current directors:
- Yogesh Kumar Gupta - Director
- Naresh Trehan - Director
- Pankaj Prakash Sahni - Director
The latest financial statements of GHL Pharma & Diagnostic on record with the MCA are for the year ended 31 March 2025. Its last annual general meeting was held on 18 September 2025. Year-wise statements from FY 2023 are in the company report.
The GSTIN of GHL Pharma & Diagnostic is 07AAJCG8809P1ZT, registered in Delhi. The company has 13 GST registrations in all, of which 13 are active. Other active GSTINs include 07AAJCG8809P2ZS (Delhi), 06AAJCG8809P1ZV (Haryana), 23AAJCG8809P1ZZ (Madhya Pradesh).
The CIN (Corporate Identification Number) of GHL Pharma & Diagnostic is U85110DL2022PTC400942. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
GHL Pharma & Diagnostic was incorporated on 29 June 2022, making it 4+ years old. It is registered with the Registrar of Companies, Delhi.
Yogesh Kumar Gupta ceased to be Additional Director on 16 Sep 2024. Yogesh Kumar Gupta was appointed as Director on 20 Mar 2024. Sanjeev Kumar ceased to be Director on 15 Dec 2023. GHL Pharma & Diagnostic has 8 board changes on record in total.
GHL Pharma & Diagnostic has 5 MSME Form 1 returns on record for the period ending Mar 2024, listing 449 overdue payments to 48 micro and small suppliers. The latest return was filed on 26 Apr 2024.
The registered office of GHL Pharma & Diagnostic is at E – 18 Defence Colony, Delhi, India – 110024.
GHL Pharma & Diagnostic operates in the healthcare industry, in the diagnostic centers and pathology labs segment.
Yes. GHL Pharma & Diagnostic was formerly known as Global Health Pharmaceutical Private Limited.
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
Swiggy Limited Listed company · 92 pages
BharatPe (Resilient Innovations Pvt Ltd) Unlisted company · 78 pages